-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
-
Media ReleaseNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media ReleaseNovartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
-
Media ReleaseNovartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
-
Media ReleaseNovartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media ReleaseNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-
Media ReleaseNovartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media ReleaseNew analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media ReleaseNovartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
-
Media ReleaseAlcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media ReleaseNovartis out-licenses three COPD products in the US
-
Media ReleaseNovartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL